PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
522.30%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses growth above 1.5x CRVO's 100.00%. Michael Burry would check for concerning trends.
230.56%
Similar operating expenses growth to CRVO's 251.41%. Walter Schloss would investigate norms.
230.56%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
243.75%
Interest expense change of 243.75% while CRVO maintains costs. Bruce Berkowitz would investigate control.
418.75%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-202.01%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-176.90%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-176.90%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
89.62%
EPS growth while CRVO declines. John Neff would investigate advantages.
89.62%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
2567.99%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
2567.99%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.